TP53 and Li-Fraumeni syndrome: A number of studies employed microarrays to evaluate global gene expression in H1299 lung cancer cells expressing p53-175H, p53-273H and p53-281G [45-47], p53-deficient HCT116 colorectal cancer cells overexpressing p53-138P and p53-175H [48], osteosarcoma U2OS cells expressing p53-157F, p53-175H and p53-248Q [49], LNCaP prostate cancer cells expressing p53-245S, p53-248W, p53-273C, p53-273H [50] as well as in Li Fraumeni syndrome-derived fibroblasts expressing p53-175H [51] have been performed.